search
Back to results

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Primary Purpose

Postoperative Pain, Bunions

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
HTX-011A
Saline Placebo
HTX-011B
HTX-002
Bupivacaine HCl
HTX-009
Sponsored by
Heron Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain focused on measuring Analgesia, Bunionectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be male or female 18 years of age or older
  2. Female subjects are eligible only if all of the following apply:

    1. Not pregnant (female subject of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test before surgery)
    2. Not lactating
    3. Not planning to become pregnant while participating in the study
    4. Be surgically sterile; or be at least two years post-menopausal; or have a monogamous partner who is surgically sterile; or be practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening visits and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days from completion of the study
  3. Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication
  4. Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia
  5. Subject has not had a contralateral bunionectomy in the non-study foot in the past 3 months
  6. Have the ability and be willing to comply with the study procedures.
  7. Must be able to understand study procedures and give informed consent for the conduct for all study procedures, using an IRB approved consent form

Exclusion Criteria:

  1. Unwilling to sign informed consent or not willing or able to complete all study procedures
  2. Have a contraindication or be allergic to any medication to be used during the trial period
  3. Have clinically significant cardiac abnormalities that, in the opinion of the investigator, would pose a health risk to the subject
  4. Have American Society of Anesthesiologists (ASA) Physical Status classification system category ≥4
  5. Have clinically significant renal or hepatic abnormalities: for example, AST or ALT > 3x ULN, creatinine > 2x ULN
  6. Have another pre-existing painful condition that may confound pain assessments
  7. Have another surgery planned within 30 days of procedure
  8. Have a known or suspected history of alcohol or drug abuse, or a positive drug screen
  9. Currently taking analgesics for a chronically painful condition, or has taken long acting opioids within 3 days of surgery, or taken any opioids within 24 hours of scheduled surgery for this study
  10. Subjects with documented sleep apnea or are on home continuous positive airway pressure (CPAP)
  11. Subjects who are receiving oxygen therapy at the time of screening
  12. Have participated in a clinical trial within 30 days of planned surgery

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Active Comparator

Active Comparator

Experimental

Experimental

Experimental

Experimental

Arm Label

HTX-011A: 200 mg

HTX-011B: 30 mg

HTX-011B : 60 mg

HTX-011B: 120 mg

HTX-011B: 200 mg

Bupivacaine HCI

Saline Placebo

HTX-002, 60 mg

HTX-002, 120 mg

HTX-002, 200 mg

HTX-009

Arm Description

HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg via injection.

HTX 011B (bupivacaine/meloxicam), 30 mg/0.9 mg via injection.

HTX-011B (bupivacaine/meloxicam) 60 mg/1.8 mg via injection or instillation.

HTX- 011B (bupivacaine/meloxicam), 120 mg/3.6 mg via injection or instillation.

HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection.

Bupivacaine HCI, 50 mg via injection.

Saline placebo via injection.

HTX- 002, 60 mg via injection.

HTX-002, 120 mg via injection.

HTX-002, 200 mg via injection.

HTX-009, 3.6 mg via injection.

Outcomes

Primary Outcome Measures

Mean Summed Pain Intensity (SPI) Score Over 24 Hours
The SPI is derived by summing the pain intensity score weighted by the scheduled time duration. SPI0-24 will be calculated by summing the Pain intensity (PI) score at the relevant time points weighted by the scheduled time duration since the prior PI assessment as follows: SPI0-24= PI1+PI2+2*PI4+2*PI6+2*PI8+2*PI10+2*PI12+2*PI14+4*PI18+6*PI24. Min = 0 (if PI=0 at every time) and Max = 240 (if PI=10 at every time).

Secondary Outcome Measures

Full Information

First Posted
May 2, 2016
Last Updated
September 13, 2023
Sponsor
Heron Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT02762929
Brief Title
Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
Official Title
A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011, HTX-002, or HTX-009 for Postoperative Analgesia Following Bunionectomy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
May 2016 (Actual)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Heron Therapeutics

4. Oversight

5. Study Description

Brief Summary
A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
Detailed Description
This study includes multiple formulations for formulation selection of the fixed-combination product and for the factorial design assessment of the contribution of each component. HTX-011A is the second formulation studied (HTX-011-49). HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies. For the factorial design assessment, HTX-002, a bupivacaine-only formulation in the same HTX-011 proprietary polymer, and HTX-009, a meloxicam-only formulation in the same HTX-011 proprietary polymer, were evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain, Bunions
Keywords
Analgesia, Bunionectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
430 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HTX-011A: 200 mg
Arm Type
Experimental
Arm Description
HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg via injection.
Arm Title
HTX-011B: 30 mg
Arm Type
Experimental
Arm Description
HTX 011B (bupivacaine/meloxicam), 30 mg/0.9 mg via injection.
Arm Title
HTX-011B : 60 mg
Arm Type
Experimental
Arm Description
HTX-011B (bupivacaine/meloxicam) 60 mg/1.8 mg via injection or instillation.
Arm Title
HTX-011B: 120 mg
Arm Type
Experimental
Arm Description
HTX- 011B (bupivacaine/meloxicam), 120 mg/3.6 mg via injection or instillation.
Arm Title
HTX-011B: 200 mg
Arm Type
Experimental
Arm Description
HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection.
Arm Title
Bupivacaine HCI
Arm Type
Active Comparator
Arm Description
Bupivacaine HCI, 50 mg via injection.
Arm Title
Saline Placebo
Arm Type
Active Comparator
Arm Description
Saline placebo via injection.
Arm Title
HTX-002, 60 mg
Arm Type
Experimental
Arm Description
HTX- 002, 60 mg via injection.
Arm Title
HTX-002, 120 mg
Arm Type
Experimental
Arm Description
HTX-002, 120 mg via injection.
Arm Title
HTX-002, 200 mg
Arm Type
Experimental
Arm Description
HTX-002, 200 mg via injection.
Arm Title
HTX-009
Arm Type
Experimental
Arm Description
HTX-009, 3.6 mg via injection.
Intervention Type
Drug
Intervention Name(s)
HTX-011A
Intervention Description
HTX-011A (bupivacaine/meloxicam), via injection.
Intervention Type
Biological
Intervention Name(s)
Saline Placebo
Intervention Description
Saline placebo via injection.
Intervention Type
Drug
Intervention Name(s)
HTX-011B
Intervention Description
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Intervention Type
Drug
Intervention Name(s)
HTX-002
Intervention Description
HTX-002, via injection.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine HCl
Intervention Description
Bupivacaine HCI, via injection.
Intervention Type
Drug
Intervention Name(s)
HTX-009
Intervention Description
HTX-009, via injection.
Primary Outcome Measure Information:
Title
Mean Summed Pain Intensity (SPI) Score Over 24 Hours
Description
The SPI is derived by summing the pain intensity score weighted by the scheduled time duration. SPI0-24 will be calculated by summing the Pain intensity (PI) score at the relevant time points weighted by the scheduled time duration since the prior PI assessment as follows: SPI0-24= PI1+PI2+2*PI4+2*PI6+2*PI8+2*PI10+2*PI12+2*PI14+4*PI18+6*PI24. Min = 0 (if PI=0 at every time) and Max = 240 (if PI=10 at every time).
Time Frame
0-24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be male or female 18 years of age or older Female subjects are eligible only if all of the following apply: Not pregnant (female subject of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test before surgery) Not lactating Not planning to become pregnant while participating in the study Be surgically sterile; or be at least two years post-menopausal; or have a monogamous partner who is surgically sterile; or be practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening visits and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days from completion of the study Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia Subject has not had a contralateral bunionectomy in the non-study foot in the past 3 months Have the ability and be willing to comply with the study procedures. Must be able to understand study procedures and give informed consent for the conduct for all study procedures, using an IRB approved consent form Exclusion Criteria: Unwilling to sign informed consent or not willing or able to complete all study procedures Have a contraindication or be allergic to any medication to be used during the trial period Have clinically significant cardiac abnormalities that, in the opinion of the investigator, would pose a health risk to the subject Have American Society of Anesthesiologists (ASA) Physical Status classification system category ≥4 Have clinically significant renal or hepatic abnormalities: for example, AST or ALT > 3x ULN, creatinine > 2x ULN Have another pre-existing painful condition that may confound pain assessments Have another surgery planned within 30 days of procedure Have a known or suspected history of alcohol or drug abuse, or a positive drug screen Currently taking analgesics for a chronically painful condition, or has taken long acting opioids within 3 days of surgery, or taken any opioids within 24 hours of scheduled surgery for this study Subjects with documented sleep apnea or are on home continuous positive airway pressure (CPAP) Subjects who are receiving oxygen therapy at the time of screening Have participated in a clinical trial within 30 days of planned surgery
Facility Information:
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
City
Bakersfield
State/Province
California
ZIP/Postal Code
93311
Country
United States
City
Pasadena
State/Province
Maryland
ZIP/Postal Code
21122
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77027
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31843865
Citation
Ottoboni T, Quart B, Pawasauskas J, Dasta JF, Pollak RA, Viscusi ER. Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain. Reg Anesth Pain Med. 2019 Dec 16:rapm-2019-100714. doi: 10.1136/rapm-2019-100714. Online ahead of print.
Results Reference
derived

Learn more about this trial

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

We'll reach out to this number within 24 hrs